
DBV Technologies S.A. DBVT
€ 18.21
0.46%
Quartalsbericht 2025-Q2
hinzugefügt 29.07.2025
DBV Technologies S.A. DPO 2011-2026 | DBVT
DPO Jährlich DBV Technologies S.A.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | 28.6 K | 5.02 K | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 28.6 K | 5.02 K | 16.8 K |
DPO anderer Aktien in der Pharmaeinzelhändler
| Name | DPO | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Adaptive Biotechnologies Corporation
ADPT
|
37.9 | $ 18.24 | -1.41 % | $ 2.68 B | ||
|
Amgen
AMGN
|
49.6 | $ 344.45 | 0.75 % | $ 185 B | ||
|
I-Mab
IMAB
|
2.24 K | - | - | $ 866 M | ||
|
Biogen
BIIB
|
65.4 | $ 178.43 | -0.81 % | $ 26 B | ||
|
Aytu BioScience
AYTU
|
186 | $ 2.7 | 3.85 % | $ 17 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
78.2 | - | - | $ 40.3 B | ||
|
Midatech Pharma plc
MTP
|
162 | - | -18.52 % | $ 27.3 M | ||
|
Acorda Therapeutics
ACOR
|
277 | - | -24.86 % | $ 820 K | ||
|
Acasti Pharma
ACST
|
4.39 K | - | 4.01 % | $ 150 M | ||
|
Akebia Therapeutics
AKBA
|
80.4 | $ 1.39 | -1.42 % | $ 261 M | ||
|
Albireo Pharma
ALBO
|
1.59 K | - | -0.23 % | $ 916 M | ||
|
Институт стволовых клеток человека
ISKJ
|
115 | - | - | - | ||
|
Ampio Pharmaceuticals
AMPE
|
2.85 K | - | -11.43 % | $ 502 K | ||
|
Aeterna Zentaris
AEZS
|
34.4 K | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
9.04 K | - | -10.17 % | $ 12.2 K | ||
|
Cardiff Oncology
CRDF
|
406 | $ 1.75 | -0.29 % | $ 83.4 M | ||
|
Compugen Ltd.
CGEN
|
123 | $ 1.85 | 0.54 % | $ 166 M | ||
|
Brickell Biotech
BBI
|
105 | - | -5.38 % | $ 6.06 M | ||
|
Amneal Pharmaceuticals
AMRX
|
21.1 | $ 14.11 | 3.14 % | $ 4.36 B | ||
|
AIkido Pharma
AIKI
|
32.8 K | - | 1.93 % | $ 17.4 M | ||
|
BioCryst Pharmaceuticals
BCRX
|
484 | $ 6.64 | 0.91 % | $ 1.37 B | ||
|
BeiGene, Ltd.
BGNE
|
915 | - | 0.49 % | $ 251 B |